Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
23 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/01/23/2593058/0/en/OncXerna-Therapeutics-Announces-Final-Results-and-New-Xerna-TME-Panel-Biomarker-Data-from-a-Phase-2-Trial-of-Bavituximab-Plus-Pembrolizumab-in-Patients-with-Previously-Untreated-Ad.html
12 Sep 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/09/12/2513841/0/en/OncXerna-Therapeutics-Announces-New-Xerna-TME-Panel-Biomarker-Data-from-Retrospective-Analysis-of-Results-from-a-Randomized-Phase-2-Trial-Evaluating-Anti-PD-1-Maintenance-Therapy-i.html
09 Sep 2022
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/oncxerna-subject-navicixizumab-trial/
08 Sep 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/09/08/2512403/0/en/OncXerna-Therapeutics-Doses-First-Patient-in-Phase-2-Trial-Evaluating-Navicixizumab-Alone-or-in-Combination-with-Chemotherapy-in-Patients-with-Select-Advanced-Solid-Tumors.html
03 Jun 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/06/03/2455957/0/en/OncXerna-Therapeutics-Announces-Upcoming-ASCO-Poster-Featuring-Data-Showing-the-Phase-2-Glioblastoma-Trial-of-Bavituximab-with-Chemoradiation-and-Adjuvant-Temozolomide-Met-its-Prim.html
ABOUT THIS PAGE